Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Famitinib vs Docetaxel in Advanced NSCLC
NCT05106335Phase 3Terminated
- Sponsor
- Hengrui
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab and famitinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hengrui. Primary endpoint: Overall Survival up to 4 years. Started Jan 2022; status: terminated.
02
Drugs
camrelizumabfamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05106335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106335.